Thermo Fisher Scientific Inc. (NYSE:TMO) Shares Sold by Kolinsky Wealth Management LLC

Kolinsky Wealth Management LLC lessened its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 7.8% in the 4th quarter, HoldingsChannel reports. The firm owned 1,745 shares of the medical research company’s stock after selling 148 shares during the quarter. Thermo Fisher Scientific makes up approximately 0.6% of Kolinsky Wealth Management LLC’s holdings, making the stock its 27th largest holding. Kolinsky Wealth Management LLC’s holdings in Thermo Fisher Scientific were worth $908,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in TMO. Wedge Capital Management L L P NC boosted its stake in Thermo Fisher Scientific by 4.1% during the fourth quarter. Wedge Capital Management L L P NC now owns 706 shares of the medical research company’s stock worth $367,000 after buying an additional 28 shares during the period. Diversify Wealth Management LLC raised its stake in Thermo Fisher Scientific by 15.9% in the 4th quarter. Diversify Wealth Management LLC now owns 4,113 shares of the medical research company’s stock valued at $2,231,000 after purchasing an additional 564 shares during the last quarter. Zhang Financial LLC increased its position in Thermo Fisher Scientific by 13.9% during the fourth quarter. Zhang Financial LLC now owns 426 shares of the medical research company’s stock worth $222,000 after purchasing an additional 52 shares during the last quarter. LaFleur & Godfrey LLC boosted its position in shares of Thermo Fisher Scientific by 9.1% in the fourth quarter. LaFleur & Godfrey LLC now owns 29,767 shares of the medical research company’s stock worth $15,486,000 after buying an additional 2,488 shares during the period. Finally, Mountain Pacific Investment Advisers LLC increased its holdings in Thermo Fisher Scientific by 2.0% during the 4th quarter. Mountain Pacific Investment Advisers LLC now owns 42,611 shares of the medical research company’s stock worth $22,168,000 after purchasing an additional 853 shares during the last quarter. 89.23% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on TMO shares. Robert W. Baird lowered their price target on Thermo Fisher Scientific from $603.00 to $573.00 and set an “outperform” rating on the stock in a report on Thursday, April 24th. Royal Bank of Canada lowered their price objective on shares of Thermo Fisher Scientific from $651.00 to $637.00 and set an “outperform” rating on the stock in a research note on Thursday, April 24th. Stifel Nicolaus lowered their target price on shares of Thermo Fisher Scientific from $665.00 to $620.00 and set a “buy” rating on the stock in a report on Thursday, April 24th. Argus reduced their target price on shares of Thermo Fisher Scientific from $620.00 to $470.00 and set a “buy” rating for the company in a report on Tuesday, April 29th. Finally, Scotiabank cut their target price on Thermo Fisher Scientific from $650.00 to $605.00 and set a “sector perform” rating for the company in a research report on Friday, April 25th. Five equities research analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $607.43.

Insider Activity

In other news, EVP Gianluca Pettiti sold 300 shares of Thermo Fisher Scientific stock in a transaction dated Monday, April 28th. The shares were sold at an average price of $429.93, for a total value of $128,979.00. Following the completion of the transaction, the executive vice president now owns 23,167 shares in the company, valued at $9,960,188.31. This trade represents a 1.28% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Marc N. Casper sold 10,000 shares of the firm’s stock in a transaction that occurred on Tuesday, March 4th. The stock was sold at an average price of $516.67, for a total transaction of $5,166,700.00. Following the completion of the transaction, the chief executive officer now directly owns 115,174 shares of the company’s stock, valued at approximately $59,506,950.58. This trade represents a 7.99% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 14,075 shares of company stock valued at $7,305,942 in the last ninety days. 0.33% of the stock is currently owned by insiders.

Thermo Fisher Scientific Trading Down 0.1%

NYSE:TMO opened at $413.47 on Wednesday. Thermo Fisher Scientific Inc. has a one year low of $390.50 and a one year high of $627.88. The company has a market cap of $156.08 billion, a PE ratio of 25.01, a PEG ratio of 2.99 and a beta of 0.82. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.66 and a quick ratio of 1.29. The firm has a 50-day moving average of $449.99 and a 200-day moving average of $508.22.

Thermo Fisher Scientific (NYSE:TMO) last posted its earnings results on Wednesday, April 23rd. The medical research company reported $5.15 earnings per share for the quarter, beating analysts’ consensus estimates of $5.10 by $0.05. Thermo Fisher Scientific had a return on equity of 17.51% and a net margin of 14.78%. The company had revenue of $10.36 billion for the quarter, compared to analyst estimates of $10.23 billion. During the same quarter last year, the company earned $5.11 earnings per share. The company’s revenue for the quarter was up .2% on a year-over-year basis. As a group, equities research analysts expect that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current fiscal year.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.